GNAI3: A Potential Drug Target and Biomarker for G protein-Coupled Receptors

Target Name: GNAI3

NCBI ID: G2773

GNAI3

GNAI3: A Potential Drug Target and Biomarker for G protein-Coupled Receptors

G protein-coupled receptors (GPCRs) are a family of transmembrane proteins that play a crucial role in cellular signaling. They are involved in various physiological processes, including sensory perception, neurotransmission, and hormone signaling. GPCRs have an attractive target for drug development due to their high selectivity and druggability. One of the GPCRs that has received significant attention in recent years is GNAI3, a protein that is known to interact with GPCRs. In this article, we will discuss GNAI3 as a drug target and biomarker for GPCRs.

GNAI3 is a protein that is composed of two subunits, GNAI1 and GNAI2. GNAI1 is a 21-kDa protein that contains a catalytic active site and several potential binding sites. GNAI2 is a 24-kDa protein that contains a catalytic active site and a N -terminus that is involved in the interaction with GPCRs. The N-terminus of GNAI2 contains a unique sequence that is known as the N-terminal hypervariable region (HVR).

GNAI3 has been shown to interact with several GPCRs, including GPCR尾2, GPCR尾3, GPCR尾4, and GPCR尾5. GNAI3 has been shown to induce receptor activation in a GPCR-expressing cell line and to interact with GPCRs in a dose-dependent manner. The interaction between GNAI3 and GPCRs are considered an attractive target for drug development due to its high selectivity and druggability.

One of the potential benefits of targeting GNAI3 is its potential as a biomarker for GPCRs. GNAI3 is a protein that is expressed in most tissues and cells, making it a potential biomarker for GPCRs. The expression of GNAI3 can be modulated by various factors, including drugs, which can be used to treat GPCRs. For example, inhibition of GNAI3 using small molecules or antibodies can be used to downregulate GPCR signaling. This can lead to a decrease in the activity of the downstream signaling pathways that are involved in GPCR signaling.

Another potential benefit of targeting GNAI3 is its potential as a drug target. GNAI3 has been shown to be a druggable protein, and various studies have shown that small molecules and antibodies can be used to inhibit GNAI3 function. GNAI3 inhibitors have been shown to be effective in preclinical studies for treating various diseases, including neurodegenerative diseases, pain, and psychiatric disorders.

In conclusion, GNAI3 is a protein that has significant potential as a drug target and biomarker for GPCRs. The interaction between GNAI3 and GPCRs makes it an attractive target for small molecules and antibodies that can be used to treat various diseases. Further research is needed to fully understand the function of GNAI3 and its potential as a drug target and biomarker for GPCRs.

Protein Name: G Protein Subunit Alpha I3

Functions: Heterotrimeric guanine nucleotide-binding proteins (G proteins) function as transducers downstream of G protein-coupled receptors (GPCRs) in numerous signaling cascades. The alpha chain contains the guanine nucleotide binding site and alternates between an active, GTP-bound state and an inactive, GDP-bound state. Signaling by an activated GPCR promotes GDP release and GTP binding. The alpha subunit has a low GTPase activity that converts bound GTP to GDP, thereby terminating the signal. Both GDP release and GTP hydrolysis are modulated by numerous regulatory proteins (PubMed:8774883, PubMed:18434541, PubMed:19478087). Signaling is mediated via effector proteins, such as adenylate cyclase. Inhibits adenylate cyclase activity, leading to decreased intracellular cAMP levels (PubMed:19478087). Stimulates the activity of receptor-regulated K(+) channels (PubMed:2535845). The active GTP-bound form prevents the association of RGS14 with centrosomes and is required for the translocation of RGS14 from the cytoplasm to the plasma membrane. May play a role in cell division (PubMed:17635935)

The "GNAI3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GNAI3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets